NCT02057380 2024-11-20
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
Astellas Pharma Inc
Phase 2 Completed
Clinical Trials
5 trialsNCT00139620 2018-02-08
A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
Astellas Pharma Inc
Phase 1 Completed
NCT01009073 2017-11-20
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
AbbVie
Phase 1 Completed
NCT00603356 2011-09-27
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
Astellas Pharma Inc
Phase 1 Completed
NCT00754104 2011-01-19
Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors
Abbott
Phase 1 Withdrawn